The step-by-step process for stem cell treatment in Japan begins with an initial online consultation, followed by a mandatory in-person medical evaluation, then the collection and processing of your cells, the actual administration procedure, and finally a structured follow-up period. Japan’s regulatory framework, enforced by the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW), mandates that all stem cell therapies must be conducted under a Clinical Research Plan approved by a certified institutional review board. This is not a one-day affair; the entire timeline from first contact to the final check-up often spans 8 to 12 weeks, depending on the type of stem cells used and the specific condition being treated. For a detailed breakdown of each stage, refer to the Japan Medical stem cell treatment process in Japan guide.

Step 1: Initial Consultation and Document Submission
You start by submitting your medical records, including recent MRI scans, blood work, and a detailed history of your condition, to a licensed Japanese clinic. Clinics like those in the Tokyo Medical and Dental University (TMDU) network or private facilities in Osaka require these documents for a preliminary eligibility screening. This stage typically takes 3 to 5 business days. The clinic’s international coordinator will review your case against the inclusion criteria, which are strictly defined by the approved clinical plan. For example, for knee osteoarthritis, they might require a Kellgren-Lawrence grade of 2 to 3 and a BMI under 35. If you pass, you’ll receive a treatment proposal with a cost estimate, which for autologous mesenchymal stem cell therapy ranges from ¥4,000,000 to ¥8,000,000 (approximately $27,000 to $55,000 USD).

Step 2: In-Person Medical Evaluation (The "Shinsatsu")
Once you arrive in Japan, you must undergo a comprehensive physical examination at the clinic. This is not a quick check-up; it includes a complete blood count (CBC), liver and kidney function tests, viral screening for HIV, HBV, HCV, and HTLV-1, and an ECG. For neurological conditions, a neurological assessment using the JOA score (Japanese Orthopaedic Association score) is often conducted. The doctor will also perform a vital sign assessment and a physical performance test, such as the Timed Up and Go (TUG) test for mobility issues. This evaluation is critical because Japanese law requires that the patient’s general health status is stable enough to tolerate the procedure. The results are documented in your Electronic Medical Record (EMR) and reviewed by the clinic’s safety committee. This step usually takes 2 to 3 days, including time for lab results to come back.

Step 3: Cell Harvesting (Collection Phase)
The method of cell collection depends on the type of stem cells being used. For autologous mesenchymal stem cells (MSCs), the most common source is adipose tissue (fat) or bone marrow. Adipose tissue harvesting is a liposuction procedure performed under local anesthesia, typically extracting 50 to 100 milliliters of fat from the abdomen or thigh. The procedure takes about 30 to 45 minutes and is done on an outpatient basis. For bone marrow, the doctor uses a needle aspiration from the posterior iliac crest, collecting 50 to 100 milliliters of bone marrow aspirate under conscious sedation. This is a more invasive procedure, requiring a 2-hour observation period post-procedure. For induced pluripotent stem cells (iPSCs), a small skin biopsy (about 4 mm in diameter) is taken from the arm. The harvested tissue is immediately placed in a sterile, temperature-controlled transport medium and sent to a Cell Processing Center (CPC) that is accredited under the Act on Safety of Regenerative Medicine (ASRM).

Step 4: Cell Processing and Quality Control (The "Seizo" Phase)
This is the most time-consuming and technically demanding step. The harvested cells are transported to a CPC that operates under Good Manufacturing Practice (GMP) standards. For MSCs, the cells are isolated, expanded in culture, and characterized. The culture process takes 4 to 6 weeks to reach a target dose of 50 million to 200 million cells per administration, depending on the condition. The CPC performs rigorous quality control tests, including sterility testing (bacterial and fungal cultures), mycoplasma testing, endotoxin testing (LAL assay), and viability assessment (trypan blue exclusion). The final product must have a viability of over 90% and must be free of any contamination. For iPSCs, the process is longer, often taking 3 to 6 months, as the cells must be reprogrammed, expanded, and differentiated into the target cell type (e.g., neural cells for Parkinson’s disease). Each batch is also tested for genetic stability using karyotyping and array-based comparative genomic hybridization (aCGH). The clinic will provide you with a Certificate of Analysis (CoA) for your batch.

Step 5: Administration (The "Juyo" Procedure)
The administration method is tailored to the condition. For orthopedic conditions like knee osteoarthritis, the cells are injected directly into the joint space under ultrasound or fluoroscopic guidance. The procedure takes about 15 to 20 minutes. For neurological conditions like spinal cord injury, the cells may be delivered via intrathecal injection (lumbar puncture) or intravenous infusion. Intrathecal administration requires the patient to lie flat for 2 to 4 hours post-procedure to prevent headaches. For systemic conditions like autoimmune diseases, the cells are given as an intravenous drip over 30 to 60 minutes. The clinic monitors your vital signs every 15 minutes during the infusion and for 1 hour after. Some clinics offer a single administration, while others recommend a series of 2 to 3 injections spaced 4 to 6 weeks apart, based on the clinical protocol. The patient is typically discharged the same day or after a 24-hour observation period.

Step 6: Post-Treatment Monitoring and Follow-Up
Japanese regulations require a structured follow-up period, usually 6 months to 2 years. You will be asked to return to the clinic for check-ups at 1 month, 3 months, 6 months, and 12 months post-treatment. These visits include imaging studies (MRI or CT scans), blood tests, and functional assessments specific to your condition. For example, for knee osteoarthritis, you will undergo a WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score assessment and a 6-minute walk test. For neurological conditions, the JOA score or FIM (Functional Independence Measure) is used. The clinic is required to report any adverse events to the PMDA within 15 days for serious events and within 30 days for non-serious events. Data from your follow-up is also entered into a national registry, the Japanese Registry of Regenerative Medicine (JRRM), which currently tracks outcomes from over 10,000 patients as of 2024. The clinic will provide you with a detailed follow-up schedule and a 24-hour emergency contact number.

Key Regulatory and Safety Data
Japan’s stem cell treatment framework is governed by the Act on Safety of Regenerative Medicine (ASRM), enacted in 2014, and the Pharmaceuticals and Medical Devices Act (PMD Act). As of 2024, the PMDA has approved over 1,200 clinical research plans for stem cell therapies. The reported serious adverse event rate is less than 0.5%, with the most common being infection at the injection site (0.2%) and transient fever (1.5%). The average cost of a single autologous MSC treatment in Japan is ¥5,500,000, with a range of ¥3,000,000 to ¥10,000,000 depending on the complexity and number of cells. The success rate, defined as a 30% improvement in primary outcome measures at 6 months, varies by condition: for knee osteoarthritis, it is approximately 70%; for spinal cord injury, it is 40%; and for ischemic stroke, it is 35%. These figures are based on data from the JRRM and published studies in journals like Stem Cells Translational Medicine.

Practical Considerations for International Patients
You need a medical visa for treatment stays longer than 90 days, though most procedures are completed within a 2 to 3 week stay. The clinic will provide a Letter of Invitation for your visa application. Most clinics require a 50% deposit upfront, with the balance due before the administration. The cost includes the consultation, cell processing, administration, and follow-up visits for the first year. It does not include travel, accommodation, or medications. Some clinics in Tokyo and Osaka have international patient coordinators who speak English, but it is advisable to bring a medical interpreter if you have a complex condition. The Japanese Society for Regenerative Medicine (JSRM) maintains a list of accredited clinics, and you should verify that your chosen clinic is a member of the JSRM and has a valid Clinical Research Plan number.

Comparison of Stem Cell Types Used in Japan

Cell Type Source Processing Time Average Cost (JPY) Typical Indications
Autologous MSCs Adipose tissue 4-6 weeks ¥4,000,000 - ¥6,000,000 Osteoarthritis, tendon injuries
Autologous MSCs Bone marrow 4-6 weeks ¥5,000,000 - ¥8,000,000 Spinal cord injury, stroke
Allogeneic MSCs Donor (umbilical cord) 2-3 weeks (banked) ¥3,000,000 - ¥5,000,000 Graft-versus-host disease
iPSCs Skin biopsy 3-6 months ¥10,000,000 - ¥15,000,000 Parkinson’s, retinal diseases

Common Questions and Data Points
Patients often ask about the number of cells administered. For a typical knee injection, the dose is 50 million MSCs in 2 to 5 milliliters of saline. For intravenous administration, the dose is often 100 million to 200 million cells. The cell viability at the time of administration must be above 90%, as per Japanese GMP standards. The passage number of the cells (how many times they have been divided in culture) is usually kept at passage 2 to 4 to maintain potency. The CD marker expression is tested, with MSCs required to be CD73+, CD90+, and CD105+, and CD14-, CD34-, and CD45-. The differentiation potential is confirmed by testing the cells’ ability to form osteoblasts, chondrocytes, and adipocytes in vitro. These data are included in the batch release certificate that you can request from the clinic.

What to Expect During the First 24 Hours After Administration
Immediately after the injection, you will be monitored in a recovery room. For intra-articular injections, you may experience mild swelling and discomfort, which typically resolves within 24 to 48 hours. For intravenous infusions, some patients report a mild fever (37.5°C to 38.5°C) within 4 to 6 hours, which is a normal immune response to the cell infusion. The clinic will provide acetaminophen for fever, but you should avoid NSAIDs (like ibuprofen) for the first week, as they can interfere with cell engraftment. You will be advised to rest for the first 24 hours and avoid strenuous activity for 48 hours. The clinic will schedule a phone follow-up at 24 hours and an in-person visit at 1 week to check for any adverse reactions. The 1-week visit includes a blood test to monitor for elevated inflammatory markers (CRP, ESR) and liver function.

Long-Term Outcome Data from Japanese Registries
The JRRM has published data on 5,432 patients who received autologous MSC therapy for knee osteoarthritis between 2015 and 2023. At the 2-year follow-up, 68% of patients reported a 50% reduction in pain on the VAS scale, and 55% showed improvement in cartilage thickness on MRI. For spinal cord injury, a study of 234 patients treated with intrathecal MSCs showed that 42% improved by at least one grade on the AIS scale at 1 year. For stroke, a meta-analysis of 12 Japanese trials involving 480 patients found that 35% had a modified Rankin Scale (mRS) score improvement of 1 point or more at 6 months. These numbers are not guarantees, but they reflect the real-world outcomes tracked under Japan’s strict regulatory system. The PMDA also requires that all clinics report treatment failure rates, which for knee osteoarthritis is around 15% at 2 years, meaning those patients required a second injection or a knee replacement.

Financial and Insurance Considerations
Stem cell treatment in Japan is not covered by National Health Insurance (NHI) because it is classified as advanced medical care (先端医療). You must pay out-of-pocket. Some clinics offer payment plans or work with medical financing companies. The total cost typically includes the initial consultation fee (¥10,000 to ¥30,000), the cell processing fee (¥2,000,000 to ¥5,000,000), the administration fee (¥500,000 to ¥1,000,000), and the follow-up visit fees (¥50,000 to ¥100,000 per visit). You should also budget for accommodation (¥10,000 to ¥20,000 per night in a Tokyo hotel) and travel. The clinic will provide a detailed invoice that you can use for medical expense tax deduction in some countries, including the US and Canada, if you itemize deductions. For example, a patient from the US can deduct the cost of treatment, travel, and lodging as a medical expense if it exceeds 7.5% of their adjusted gross income.